Pathophysiology of diabetic dyslipidemia:implications for atherogenesis and treatment

Bibliography

• Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with Type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N. Engl. J. Med. 339(4), 229–234 (1998)
   Google Scholar
• Schramm TK, Gislason GH, Kober L et al. Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk: a population study of 3 million people. Circulation 117(15), 1945–1954 (2008)
   Google Scholar
• Krempf M, Parhofer KG, Steg PG et al. Cardiovascular event rates in diabetic and nondiabetic individuals with and without established atherothrombosis (from the Reduction of Atherothrombosis for Continued Health [REACH] Registry). Am. J. Cardiol. 105(5), 667–671 (2010)
   Google Scholar
• Lee CD, Folsom AR, Pankow JS, Brancati FL. Cardiovascular events in diabetic and nondiabetic adults with or without history of myocardial infarction. Circulation 109(7), 855–860 (2004)
   Google Scholar
• Booth GL, Kapral MK, Fung K, Tu JV. Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: a population-based retrospective cohort study. Lancet 368(9529), 29–36 (2011)
   Google Scholar
• Alexander CM, Landsman PB, Teutsch SM, Haffner SM. NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES II participants age 50 years and older. Diabetes 52(5), 1210–1214 (2003)
   Google Scholar
• Findeisen HM, Weckbach S, Stark RG, Reiser MF, Schoenberg SO, Parhofer KG. Metabolic syndrome predicts vascular changes in whole body magnetic resonance imaging in patients with long standing diabetes mellitus. Cardiovasc. Diabetol. 9, 44 (2010).
   Google Scholar
• An MRI study which shows that in patients with long-standing diabetes vascular changes are closely related to the factors defining the metabolic syndrome.
   Google Scholar
• Gerstein HC, Miller ME, Byington RP et al. Effects of intensive glucose lowering in Type 2 diabetes. N. Engl. J. Med. 358(24), 2545–2559 (2008)
   Google Scholar
• Patel A, Macmahon S, Chalmers J et al. Intensive blood glucose control and vascular outcomes in patients with Type 2 diabetes. N. Engl. J. Med. 358(24), 2560–2572 (2008)
   Google Scholar
• Alberti KG, Eckel RH, Grundy SM et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120(16), 1640–1645 (2011)
   Google Scholar
• Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in Type 2 diabetes. N. Engl. J. Med. 358(6), 580–591 (2008).
   Google Scholar
• A Danish study demonstrating that in patients with Type 2 diabetes mellitus a multifactorial approach aggressively addressing lipids, glucose and blood pressure is superior to conventional therapy with respect to preventing cardiovascular events. A follow-up investigation demonstrates that mortality was also reduced by the more aggressive approach.
   Google Scholar
• Parhofer KG, Laubach E, Barrett PH. Effect of atorvastatin on postprandial lipoprotein metabolism in hypertriglyceridemic patients. J. Lipid. Res. 44(6), 1192–1198 (2003)
   Google Scholar
• Taskinen MR. Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia 46(6), 733–749 (2003)
   Google Scholar
• Adiels M, Olofsson SO, Taskinen MR, Boren J. Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome. Arterioscler. Thromb. Vasc. Biol. 28(7), 1225–1236 (2008).
   Google Scholar
• Excellent review on the cellular and molecular mechanisms linking diabetes to VLDL overproduction.
   Google Scholar
• Shelness GS, Sellers JA. Very-low-density lipoprotein assembly and secretion. Curr. Opin. Lipid. 12(2), 151–157 (2001)
   Google Scholar
• Pullinger CR, North JD, Teng BB, Rifici VA, Ronhild De Brito AE, Scott J. The apolipoprotein B gene is constitutively expressed in HepG2 cells: regulation of secretion by oleic acid, albumin, and insulin, and measurement of the mRNA half-life. J. Lipid. Res. 30(7), 1065–1077 (1989)
   Google Scholar
• Parhofer KG, Barrett PH. Thematic review series: patient-oriented research. What we have learned about VLDL and LDL metabolism from human kinetics studies. J. Lipid. Res. 47(8), 1620–1630 (2011)
   Google Scholar
• Packard CJ, Demant T, Stewart JP et al. Apolipoprotein B metabolism and the distribution of VLDL and LDL subfractions. J. Lipid. Res. 41(2), 305–318 (2000)
   Google Scholar
• Verges B: Abnormal hepatic apolipoprotein B metabolism in Type 2 diabetes. Atherosclerosis 211(2), 353–360 (2010).
   Google Scholar
• Very good review article on the abnormal apoB metabolism in diabetic subjects.
   Google Scholar
• Neumeier M, Sigruener A, Eggenhofer E et al. High molecular weight adiponectin reduces apolipoprotein B and E release in human hepatocytes. Biochem. Biophys. Res. Commun. 352(2), 543–548 (2007)
   Google Scholar
• Ng TW, Watts GF, Farvid MS, Chan DC, Barrett PH. Adipocytokines and VLDL metabolism: independent regulatory effects of adiponectin, insulin resistance, and fat compartments on VLDL apolipoprotein B-100 kinetics? Diabetes 54(3), 795–802 (2005)
   Google Scholar
• Qiao L, Zou C, Van Der Westhuyzen DR, Shao J. Adiponectin reduces plasma triglyceride by increasing VLDL triglyceride catabolism. Diabetes 57(7), 1824–1833 (2008)
   Google Scholar
• Lapointe A, Tchernof A, Lamarche B et al. Plasma adiponectin concentration is strongly associated with VLDL TG catabolism in postmenopausal women. Nut. Metab. Cardiovasc. Dis. 21(4), 254–260 (2010)
   Google Scholar
• Mero N, Malmstrom R, Steiner G, Taskinen MR, Syvanne M. Postprandial metabolism of apolipoprotein B-48-and B-100-containing particles in Type 2 diabetes mellitus: relations to angiographically verified severity of coronary artery disease. Atherosclerosis 150(1), 167–177 (2000)
   Google Scholar
• Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 298(3), 299–308 (2007)
   Google Scholar
• Tushuizen ME, Diamant M, Heine RJ. Postprandial dysmetabolism and cardiovascular disease in Type 2 diabetes. Postgrad. Med. J. 81(951), 1–6 (2005)
   Google Scholar
• Duez H, Lamarche B, Uffelman KD, Valero R, Cohn JS, Lewis GF. Hyperinsulinemia is associated with increased production rate of intestinal apolipoprotein B-48-containing lipoproteins in humans. Arterioscler. Thromb. Vasc. Biol. 26(6), 1357–1363 (2011)
   Google Scholar
• Hogue JC, Lamarche B, Tremblay AJ, Bergeron J, Gagne C, Couture P. Evidence of increased secretion of apolipoprotein B-48-containing lipoproteins in subjects with Type 2 diabetes. J. Lipid. Res. 48(6), 1336–1342 (2007).
   Google Scholar
• A kinetic study using stable isotope methodology to evaluate postprandial lipoprotein metabolism in diabetic subjects. The study demonstrates that the increased concentration of apoB48, VLDL apoB100, and IDL apoB100 is the result of increased production rates and reduced fractional catabolic rates of these lipoprotein subfractions.
   Google Scholar
• Tushuizen ME, Pouwels PJ, Bontemps S et al. Postprandial lipid and apolipoprotein responses following three consecutive meals associate with liver fat content in Type 2 diabetes and the metabolic syndrome. Atherosclerosis 211(1), 308–314 (2010)
   Google Scholar
• Feingold KR, Grunfeld C. The role of HDL in innate immunity. J. Lipid. Res. 52(1), 1–3 (2011)
   Google Scholar
• Tall AR. Cholesterol efflux pathways and other potential mechanisms involved in the athero-protective effect of high density lipoproteins. J. Int. Med. 263(3), 256–273 (2008).
   Google Scholar
• Excellent review on the mechanisms linking HDL with atherosclerosis. Although the review focuses on reverse cholesterol transport.
   Google Scholar
• Barter PJ. Hugh sinclair lecture: the regulation and remodelling of HDL by plasma factors. Atheroscler. Suppl. 3(4), 39–47 (2002)
   Google Scholar
• Grundy SM, Cleeman JI, Merz CN et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel II guidelines. Circulation 110(2), 227–239 (2004)
   Google Scholar
• Barter P, Gotto AM, Larosa JC et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N. Engl. J. Med. 357(13), 1301–1310 (2007)
   Google Scholar
• Barter PJ, Caulfield M, Eriksson M et al. Effects of torcetrapib in patients at high risk for coronary events. N. Engl. J. Med. 357(21), 2109–2122 (2007)
   Google Scholar
• Guerin M, Le Goff W, Duchene E et al. Inhibition of CETP by torcetrapib attenuates the atherogenicity of postprandial TG-rich lipoproteins in type IB hyperlipidemia. Arterioscler. Thromb. Vasc. Biol. 28(1), 148–154 (2008)
   Google Scholar
• Brinton EA, Eisenberg S, Breslow JL. Human HDL cholesterol levels are determined by apoA-I fractional catabolic rate, which correlates inversely with estimates of HDL particle size. Effects of gender, hepatic and lipoprotein lipases, triglyceride and insulin levels, and body fat distribution. Arterioscler. Thromb. 14(5), 707–720 (1994)
   Google Scholar
• Ji J, Watts GF, Johnson AG et al. High-density lipoprotein (HDL) transport in the metabolic syndrome: application of a new model for HDL particle kinetics. J. Clin. Endocrinol. Metab. 91(3), 973–979 (2011).
   Google Scholar
• A kinetic study demonstrating that men with the metabolic syndrome exhibit a number of abnormalities in HDL metabolism: hypercatabolism of the two major HDL lipoprotein particles, LpA-I and LpA-I:A-I, but selective overproduction of LpA-I
   Google Scholar
• Pietzsch J, Julius U, Nitzsche S, Hanefeld M. In vivo evidence for increased apolipoprotein A-I catabolism in subjects with impaired glucose tolerance. Diabetes 47(12), 1928–1934 (1998)
   Google Scholar
• Ikewaki K, Zech LA, Kindt M, Brewer HB Jr, Rader DJ. Apolipoprotein A-I production rate is a major factor regulating the distribution of apolipoprotein A-I among HDL subclasses LpA-I and LpA-I:A-I in normolipidemic humans. Arterioscler. Thromb. Vasc. Biol. 15(3), 306–312 (1995)
   Google Scholar
• Schaefer EJ, Ordovas JM. Metabolism of apolipoproteins A-I, A-I, and A-IV. Methods Enzymol. 129, 420–443 (1986)
   Google Scholar
• Bilz S, Wagner S, Schmitz M, Bedynek A, Keller U, Demant T. Effects of atorvastatin versus fenofibrate on apoB-100 and apoA-I kinetics in mixed hyperlipidemia. J. Lipid. Res. 45(1), 174–185 (2004)
   Google Scholar
• Chan DC, Watts GF, Nguyen MN, Barrett PH. Factorial study of the effect of n-3 fatty acid supplementation and atorvastatin on the kinetics of HDL apolipoproteins A-I and A-I in men with abdominal obesity. Am. J. Clin. Nut. 84(1), 37–43 (2011)
   Google Scholar
• Lamon-Fava S, Diffenderfer MR, Barrett PH et al. Effects of different doses of atorvastatin on human apolipoprotein B-100, B-48, and A-I metabolism. J. Lipid. Res. 48(8), 1746–1753 (2007)
   Google Scholar
• Mauger JF, Couture P, Paradis ME, Lamarche B. Comparison of the impact of atorvastatin and simvastatin on apoA-I kinetics in men. Atherosclerosis 178(1), 157–163 (2005)
   Google Scholar
• Ooi EM, Watts GF, Nestel PJ, Sviridov D, Hoang A, Barrett PH. Dose-dependent regulation of high-density lipoprotein metabolism with rosuvastatin in the metabolic syndrome. J. Clin. Endocrinol. Metab. 93(2), 430–437 (2008)
   Google Scholar
• Verges B, Florentin E, Baillot-Rudoni S et al. Rosuvastatin 20 mg restores normal HDL-apoA-I kinetics in Type 2 diabetes. J. Lipid. Res. 50(6), 1209–1215 (2011)
   Google Scholar
• Geiss HC, Otto C, Schwandt P, Parhofer KG. Effect of atorvastatin on low-density lipoprotein subtypes in patients with different forms of hyperlipoproteinemia and control subjects. Metabolism 50(8), 983–988 (2001)
   Google Scholar
• Austin MA, Edwards KL. Small, dense low density lipoproteins, the insulin resistance syndrome and noninsulin-dependent diabetes. Curr. Opin. Lipidol. 7(3), 167–171 (1996)
   Google Scholar
• Superko HR, Gadesam RR. Is it LDL particle size or number that correlates with risk for cardiovascular disease? Curr. Atheroscler. Rep. 10(5), 377–385 (2008)
   Google Scholar
• Chait A, Brazg RL, Tribble DL, Krauss RM. Susceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B. Am. J. Med. 94(4), 350–356 (1993)
   Google Scholar
• Galeano NF, Al-Haideri M, Keyserman F, Rumsey SC, Deckelbaum RJ. Small dense low density lipoprotein has increased affinity for LDL receptor-independent cell surface binding sites: a potential mechanism for increased atherogenicity. J. Lipid. Res. 39(6), 1263–1273 (1998)
   Google Scholar
• Berneis KK, Krauss RM. Metabolic origins and clinical significance of LDL heterogeneity. J. Lipid. Res. 43(9), 1363–1379 (2002)
   Google Scholar
• Packard CJ, Shepherd J. Lipoprotein heterogeneity and apolipoprotein B metabolism. Arterioscler. Thromb. Vasc. Biol. 17(12), 3542–3556 (1997)
   Google Scholar
• Geiss HC, Bremer S, Barrett PH, Otto C, Parhofer KG. In vivo metabolism of LDL subfractions in patients with heterozygous FH on statin therapy: rebound analysis of LDL subfractions after LDL apheresis. J. Lipid. Res. 45(8), 1459–1467 (2004)
   Google Scholar
• Campos H, Arnold KS, Balestra ME, Innerarity TL, Krauss RM. Differences in receptor binding of LDL subfractions. Arterioscler. Thromb. Vasc. Biol. 16(6), 794–801 (1996)
   Google Scholar
• Nigon F, Lesnik P, Rouis M, Chapman MJ. Discrete subspecies of human low density lipoproteins are heterogeneous in their interaction with the cellular LDL receptor. J. Lipid. Res. 32(11), 1741–1753 (1991)
   Google Scholar
• Guerin M, Le Goff W, Lassel TS, Van Tol A, Steiner G, Chapman MJ. Atherogenic role of elevated CE transfer from HDL to VLDL(1) and dense LDL in Type 2 diabetes: impact of the degree of triglyceridemia. Arterioscler. Thromb. Vasc. Biol. 21(2), 282–288 (2001)
   Google Scholar
• De Graaf J, Hak-Lemmers HL, Hectors MP, Demacker PN, Hendriks JC, Stalenhoef AF. Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subfraction in healthy subjects. Arterioscler. Thromb. 11(2), 298–306 (1991)
   Google Scholar
• Tan KC, Ai VH, Chow WS, Chau MT, Leong L, Lam KS. Influence of low density lipoprotein (LDL) subfraction profile and LDL oxidation on endothelium-dependent and independent vasodilation in patients with Type 2 diabetes. J. Clin. Endocrinol. Metab. 84(9), 3212–3216 (1999)
   Google Scholar
• Goulinet S, Chapman MJ. Plasma LDL and HDL subspecies are heterogenous in particle content of tocopherols and oxygenated and hydrocarbon carotenoids. Relevance to oxidative resistance and atherogenesis. Arterioscler. Thromb. Vasc. Biol. 17(4), 786–796 (1997)
   Google Scholar
• Barter PJ, Nicholls S, Rye KA, Anantharamaiah GM, Navab M, Fogelman AM. Antinflammatory properties of HDL. Circ. Res. 95(8), 764–772 (2004)
   Google Scholar
• Von Eckardstein A, Hersberger M, Rohrer L. Current understanding of the metabolism and biological actions of HDL. Curr. Opin. Clin. Nutr. Metab. Care 8(2), 147–152 (2005)
   Google Scholar
• Sorrentino SA, Besler C, Rohrer L et al. Endothelial-vasoprotective effects of high-density lipoprotein are impaired in patients with Type 2 diabetes mellitus but are improved after extended-release niacin therapy. Circulation 121(1), 110–122 (2010).
   Google Scholar
• An elegant study demonstrating that HDL from diabetic patients have substantially impaired endothelial protective effects compared with HDL from healthy subjects.
   Google Scholar
• Kearney PM, Blackwell L, Collins R et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 371(9607), 117–125 (2008)
   Google Scholar
• Zambon S, Romanato G, Sartore G et al. Bariatric surgery improves atherogenic LDL profile by triglyceride reduction. Obes. Surg. 19(2), 190–195 (2011)
   Google Scholar
• Siri-Tarino PW, Williams PT, Fernstrom HS, Rawlings RS, Krauss RM. Reversal of small, dense LDL subclass phenotype by normalization of adiposity. Obesity (Silver Spring) 17(9), 1768–1775 (2011)
   Google Scholar
• Parhofer KG, Laubach E, Geiss HC, Otto C. [Effect of glucose control on lipid levels in patients with Type 2 diabetes]. Dtsch. Med. Wochenschr. 127(18), 958–962 (2002)
   Google Scholar
• Parhofer KG, Otto C, Geiss HC, Laubach E, Goke B. Effect of pioglitazone on lipids in well controlled patients with diabetes mellitus Type 2 – results of a pilot study. Exp. Clin. Endocrinol. Diabetes 113(1), 49–52 (2005)
   Google Scholar
• Tremblay AJ, Lamarche B, Deacon CF, Weisnagel SJ, Couture P. Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with Type 2 diabetes. Diabetes Obes. Metab. 13(4), 366–373 (2011)
   Google Scholar
• Baigent C, Keech A, Kearney PM et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366(9493), 1267–1278 (2005).
   Google Scholar
• Meta-analysis on the effect of statins, demonstrating that diabetic subjects benefit from such therapy as much as nondiabetic subjects
   Google Scholar
• Rubins HB, Robins SJ, Collins D et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. veterans affairs high-density lipoprotein cholesterol intervention trial study group. N. Engl. J. Med. 341(6), 410–418 (1999)
   Google Scholar
• Keech A, Simes RJ, Barter P et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with Type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366(9500), 1849–1861 (2005)
   Google Scholar
• Ginsberg HN, Elam MB, Lovato LC et al. Effects of combination lipid therapy in Type 2 diabetes mellitus. N. Engl. J. Med. 362(17), 1563–1574 (2010)
   Google Scholar
• Sprecher DL. Raising high-density lipoprotein cholesterol with niacin and fibrates: a comparative review. Am. J. Cardiol. 86(12A), 46L–50L (2000).
   Google Scholar